BSE filing, NSE: ELANTAS. Summary written from the filing by ALFA Finder's alert engine.
Elantas Beck India Ltd: key numbers
- Share price
- ₹12,696.25
- Market cap
- ₹10,065 Cr
- Revenue (annual)
- ₹847.8 Cr
- Net profit (annual)
- ₹147.8 Cr
- P/E (TTM)
- 56.7×Sector 34.1×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 0.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Elantas Beck India Ltd
All →Elantas Beck India Q2 FY27 Results: Net Profit ₹45.5 Cr, Up 25.3% YoY
Elantas Beck India Ltd reported revenue from operations of ₹265.3 Cr (+22.5% YoY) and net profit of ₹45.5 Cr (+25.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹45.5 Cr · +25.3% YoY
Elantas Beck India Management Change
Mr. Sanjay Kulkarni has resigned from his position as Chief Financial Officer and Key Managerial Personnel of ELANTAS Beck India Ltd, effective October 21, 2026.
Elantas Beck India Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Elantas Beck India Board Meeting Date
ELANTAS Beck India schedules its Board meeting for 28 October 2026 to approve Q1 and nine-month results. Trading window remains closed until 48 hours post-declaration.
Elantas Beck India Q1 FY27 Results: Net Profit ₹70.9 Cr, Up 80.4% YoY
Elantas Beck India Ltd reported revenue from operations of ₹283.4 Cr (+35.0% YoY) and net profit of ₹70.9 Cr (+80.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹70.9 Cr · +80.4% YoY
Elantas Beck India Board Meeting Date
Elantas Beck India Ltd scheduled a Board Meeting for August 4, 2026. The board will consider and approve unaudited financial results for the period ended June 30, 2026.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
KFIN Technologies Regulatory Approval
KFin Technologies' Thai subsidiary received a Foreign Business License from Thailand's Ministry of Commerce. The license enables the subsidiary to conduct permitted business activities under local law.